Stockscreener 앱 받기
17.95
1.05%
-0.1955
전일 마감가:
$18.15
열려 있는:
$18.15
하루 거래량:
263.37K
Relative Volume:
0.31
시가총액:
$2.04B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-12.82
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-1.91%
1개월 성능:
+8.91%
6개월 성능:
+8.06%
1년 성능:
+21.52%
1일 변동 폭
$17.61
$18.15
1주일 범위
$17.46
$18.52
52주 변동 폭
$14.17
$34.13
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.96 | 2.04B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
132.31 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.64 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.56 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.52 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.44 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com
What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News
Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st
H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada
NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com
Why NovoCure Stock Skyrocketed This Week - Yahoo Finance
H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com
NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey
NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World
NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune
Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks
NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges - TipRanks
NovoCure (NVCR) Stock Rises on Strong Quarterly Earnings - GuruFocus
Novocure (NVCR) Sees Early Revenue from Lung Cancer Treatments | NVCR Stock News - GuruFocus
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 - Benzinga
Novocure’s device for metastatic NSCLC treatment gains CE Mark - MSN
NovoCure (NVCR) Reports Strong Q1 Revenue Growth Amid Optune Lua Expansion - GuruFocus
Stocks of NovoCure Ltd (NVCR) are poised to climb above their peers - Sete News
NovoCure Surpasses Q1 Expectations - Mitrade
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
NovoCure Surpasses Q1 Expectations - The Motley Fool
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats E - GuruFocus
Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com India
Novocure Reports First Quarter 2025 Financial Results | NVCR Sto - GuruFocus
Novocure (NVCR) Surpasses Q1 Revenue Projections, Reports $154.9 - GuruFocus
NovoCure Ltd Reports Q1 2025 Earnings: EPS Loss of $0.31 Beats Estimate, Revenue of $155 Million Exceeds Expectations - GuruFocus
Novocure Reports First Quarter 2025 Financial Results - TradingView
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025 - TipRanks
NovoCure's Earnings: A Preview - Benzinga
Novocure (NVCR) to Showcase Key PANOVA-3 Trial Findings at ASCO 2025 | NVCR Stock News - GuruFocus
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical T - GuruFocus
Novocure price target lowered to $34 from $42 at Piper Sandler - TipRanks
Novocure (NVCR) Faces Revised Price Target Amid Investor Opportu - GuruFocus
Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News - GuruFocus
Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget - Mugglehead Magazine
Novocure (NVCR) Gains CE Mark for Optune Lua in Lung Cancer Treatment | NVCR Stock News - GuruFocus
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer | NVCR Stock News - GuruFocus
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
LPL Financial LLC Acquires Shares of 27,861 NovoCure Limited (NASDAQ:NVCR) - Defense World
Form DEFA14A NovoCure Ltd - StreetInsider
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Mar 03 '25 |
Sale |
18.54 |
2,527 |
46,841 |
143,673 |
| Cordova Ashley | Chief Executive Officer |
Mar 03 '25 |
Sale |
18.54 |
2,053 |
38,055 |
204,005 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 03 '25 |
Sale |
18.54 |
250 |
4,634 |
29,173 |
10.06%
0.08%
자본화:
|
볼륨(24시간):